Treatments for suppression of lactation

Oladapo, Olufemi T.; Fawole, Bukola

doi:10.1002/14651858.cd005937.pub2

Cited by 25 publications

(35 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While this drop in progesterone appears to be the key trigger, estrogen withdrawal also accompanies secretory activation. Some studies have found that estrogen alone is effective in suppressing lactation; however, these studies involved administration of different types of estrogen at different doses and time frames than those given for contraceptive purposes [41]. Paradoxically, although a drop in estrogen correlates with lactation initiation, estrogen actually stimulates prolactin release [42].…”

Section: Discussionmentioning

confidence: 99%

Combined hormonal contraceptive use among breastfeeding women: an updated systematic review

et al. 2016

View full text Add to dashboard Cite

Limited evidence of poor to fair quality demonstrates an inconsistent impact of COCs on breastfeeding duration and success. The evidence also demonstrated conflicting results on whether early initiation of COCs affects infant outcomes but generally found no negative impact on infant outcomes with later initiation of COCs. The body of evidence is limited by older studies using different formulations and doses of estrogen and poor methodologic quality. Given the significant limitations of this body of evidence, the importance of contraception for postpartum women and the theoretical concerns that have been raised about the use of combined hormonal contraception by women who are breastfeeding, rigorous studies examining these issues are needed. In addition, postpartum women should be counseled about the full range of safe alternative contraceptive methods, particularly during the first 6 weeks postpartum when the risk of venous thromboembolism is highest and use of estrogen may exacerbate this risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined hormonal contraceptive use among breastfeeding women: an updated systematic review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…2 The same review reported that there were several trials supporting the efficacy of bromocriptine in suppressing lactation but concluded that there was weak evidence that it is better than having no treatment. 2 In addition, there are significant ergot side-effects with bromocriptine, including cardiovascular events. These side-effects are much less common with cabergoline, which is an effective lactation suppressant.…”

Section: Discussionmentioning

confidence: 99%

Survey of lactation suppression in HIV-positive pregnant women

Pammi

Carlin

2012

Int J STD AIDS

View full text Add to dashboard Cite

The risk of HIV transmission via breastfeeding is well reported. We conducted a national survey in the UK to look at the current knowledge and postpartum practice of HIV physicians caring for HIV-positive pregnant women. In total, 167 questionnaires were distributed, 85 (51%) questionnaires were returned. All the respondents advised their patients against breastfeeding, 17 (23%) respondents routinely prescribed drugs for postpartum lactation suppression and 32 (43%) detailed awareness of interactions between antiretroviral therapy and dopaminergic lactation suppression agents. Thirteen respondents reported awareness of guidance on lactation suppression. The knowledge and use of lactation suppression agents appears to be low. However, its use will not only reduce postnatal mastitis and breast engorgement but will also help women deal with social pressures to breastfeed. Increased use in specific circumstances will improve the postnatal care of HIV-positive pregnant women in the UK.

show abstract

“…Une méta-analyse, portant sur les traitements inhibant la lactation, a inclus 46 essais cliniques (5164 patientes) [3]. Les données permettant une prise en charge optimale de l'inhibition de la lactation étaient jugées insuffisantes.…”

Section: Discussionunclassified

“…Depuis, elle est toujours commercialisée avec un renforcement des informations du résumé des caractéristiques du produit (RCP) relatives aux précautions à prendre chez les patientes à risque et au nécessaire respect des contre-indications. La notification régulière d'effets indésirables graves associés à la bromocriptine chez des femmes jeunes a conduit à s'orienter vers des alternatives thérapeutiques [3]. D'autres dérivés de l'ergot de seigle ayant une autorisation de mise sur le marché (AMM), comme le lisuride (Arolac ® ), ou utilisés hors AMM, comme la dihydroergocryptine associée à la caféine (Vasobral ® ) [4,5] et la cabergoline (Dostinex ® ) [6] paraissent de plus en plus prescrits dans l'inhibition de la lactation.…”

Section: Introductionunclassified